Nanomedicine review: clinical developments in liposomal applications

Cancer Nanotechnology

Table 8 Toxicity of the clinical trials with daunorubicin

References	Disease	LF	Toxicity Grade 3–5 (%)
References	Disease	LF	FN	B	P	H	S	F	ARF	UTI	R	H_t	RF	C
Inman (2017)	AML	CPX-351	68	10	20		9					10	7
Cortes et al. (2015)	AML	CPX-351	54	30	17	9	9	15	5	6	11	5
Lancet et al. (2014)	AML	CPX-351	63.5	35	15	15	12	9	9	7	8
Gergis et al. (2013)	AML	CPX-351												3^a
Karspers et al. (2013)	AML	DaunoXome^® + fludarabine + cytarabine + filgrastim												2.7
Creutzig et al. (2013)	AML	Liposomal daunorubicin									3.6		16	2.1

In the blanks, this type of toxicity is not reported
AML acute myeloid leukemia, LF liposomal formulation, FN febrile neutropenia, B bacteremia, P pneumonia, H hypokalemia, S sepsis, F fatigue, ARF acute renal failure, UTI urinary tract infection, R rash, H_t hypertension, RF respiratory failure, C cardiotoxicity
^aGrade 2

ISSN: 1868-6966